H.C. Wainwright reiterates Absci stock rating on hair loss data By Investing.com

H.C. Wainwright reiterated a Buy on Absci with an $8.00 price target, citing Veradermics' Phase 2/3 hair-loss data as a new efficacy benchmark and saying ABS-201 could be differentiated if it exceeds a 40 hairs/cm² TAHC gain at 26 weeks. Absci expects initial 13-week proof-of-concept data from HEADLINE in 2H26 and 26-week data in early 2027. Offseting the bullish biotech commentary, Absci's Q4 2025 results missed expectations with EPS of -$0.20 versus -$0.18 consensus and revenue of $700,000 versus $1.38 million expected.

Analysis

The market is increasingly treating efficacy in pattern hair loss as a relative race rather than an absolute binary, which matters because the first credible read-through from Veradermics effectively compresses the acceptable bar for every follow-on program. That is bullish for differentiated assets with clean safety, but it also raises the probability of a near-term valuation reset for names that are still years from proving they can outperform the new midpoint benchmark. For ABSI, the key issue is not just whether it works, but whether the company can generate enough signal at 13 weeks to avoid being valued as a distant, high-burn story with optionality rather than a clinical asset.

The second-order winner is likely any company in the “adjacent platform” bucket that can claim speed, lower systemic risk, or easier dosing, because commercial adoption in alopecia is likely to be driven by adherence and tolerability as much as efficacy. The biggest loser in the medium term is not one competitor but the entire cohort of pre-proof assets: the market will start discounting future readouts by a higher evidentiary hurdle, which mechanically lowers expected probability-adjusted value. That creates a window where better-capitalized names with nearer catalysts can outperform while earlier-stage platforms get punished for execution lag.

Near term, the stock is more event-volatility than fundamentals. The earnings miss reinforces that any drawdown on weak quarterly numbers can be bought only if investors are willing to underwrite a 12-18 month clinical waiting period; otherwise the financing overhang dominates until the first proof-of-concept data. A failure to show meaningful separation at 13 weeks would likely trigger a sharper de-rating than the upside from merely “meeting expectations,” because the current setup already bakes in a premium for differentiated efficacy.

The contrarian angle is that the market may be underestimating how much a clean safety profile can matter in a chronic cosmetic indication: even modest efficacy can become commercially meaningful if dosing is simpler and side effects are materially lower than incumbents. Conversely, the consensus may be overextrapolating a single competitor’s readout into a durable class-wide benchmark, when in reality hair-loss markets often reward a combined package of efficacy, tolerability, and convenience. That makes this a better trading story than long-duration fundamental story until ABS-201 de-risks.

Key Decisions for Investors

• Stay tactical on ABSI: trade around catalysts rather than initiate a core long before 2H26 data; risk/reward is skewed negatively until the company proves separation at 13 weeks.
• If holding ABSI, consider a call spread financed by upside trim around the next readout window (e.g., 2026-dated calls) to express optionality while capping downside from a failed interim signal.
• Pair trade: long any nearer-term, better-capitalized hair-loss beneficiary vs. short ABSI into the pre-data period; the setup favors names with lower burn and closer monetization over distant binary exposure.
• For event-driven accounts, buy ABSI only on post-earnings or broad biotech selloffs and size small; the trade should target a 2-3x payoff on positive proof-of-concept but must tolerate high probability of dead money for 12+ months.
• Set a hard risk trigger: if the market starts marking down preclinical alopecia peers after the Veradermics benchmark resets sentiment, reduce exposure across the basket—this is where multiple compression can outrun fundamental progress.